The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection

被引:192
作者
Bentrem, D
Wilton, A
Mazumdar, M
Brennan, M
Coit, D
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
cytology; stomach neoplasm; staging; metastasis; peritoneal lavage;
D O I
10.1245/ASO.2005.03.065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although positive peritoneal cytology is associated with poor prognosis, it has not been found to be independently predictive of outcome when evaluated in context of post-resection pathologic T and N stage. This study was undertaken to evaluate the predictive value of positive cytology in context of other prognostic factors available prior to surgery in patients undergoing R0 resection for gastric cancer, to assess its role in selecting patients for appropriate treatment prior to surgical resection. Methods: Clinical variables for all patients undergoing R0 resection for gastric adenocarcinoma at Memorial Sloan-Kettering Cancer Center from 1993-2002 were reviewed from a prospective database. Patients underwent preoperative assessment of T and N stage with CT scan, laparoscopy, and endoscopic and/or laparoscopic ultrasound. Peritoneal cytology was obtained in all patients. Results: Patients with gastric cancer (n = 371) underwent R0 resection and staging laparoscopy with peritoneal washings; 24 patients (6.5%) had positive peritoneal cytology. Positive cytology was associated with advanced T stage (P = 0.02) but not with nodal positivity (P = 0.11). Median survival of patients with positive cytology was 14.8 months vs. 98.5 months for patients with negative cytology (P < 0.001). Multivariate analysis identified preoperative T stage, preoperative N stage, site, and cytology as significant predictors of outcome. Positive cytology was the preoperative factor most predictive of death from gastric cancer (RR 2.7, P < 0.001). Conclusions: Positive cytology is information potentially available preoperatively that identifies a patient population at very high risk for early recurrence and death after curative resection of gastric cancer.
引用
收藏
页码:347 / 353
页数:7
相关论文
共 30 条
  • [1] CURATIVE RESECTION OF GASTRIC-CANCER - LIMITATION OF PERITONEAL-LAVAGE CYTOLOGY IN PREDICTING THE OUTCOME
    ABE, S
    YOSHIMURA, H
    TABARA, H
    TACHIBANA, M
    MONDEN, N
    NAKAMURA, T
    NAGAOKA, S
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1995, 59 (04) : 226 - 229
  • [2] Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma
    Bando, E
    Yonemura, Y
    Takeshita, Y
    Taniguchi, K
    Yasui, T
    Yoshimitsu, Y
    Fushida, S
    Fujimura, T
    Nishimuua, G
    Miwa, K
    [J]. AMERICAN JOURNAL OF SURGERY, 1999, 178 (03) : 256 - 262
  • [3] Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer
    Benevolo, M
    Mottolese, M
    Cosimelli, M
    Tedesco, M
    Giannarelli, D
    Vasselli, S
    Carlini, M
    Garofalo, A
    Natali, PG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3406 - 3411
  • [4] Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer
    Bonenkamp, JJ
    Songun, I
    Hermans, J
    vandeVelde, CJH
    vanElk, P
    Gouma, DJ
    Obertop, H
    Taat, CW
    Meyer, S
    Plukker, J
    Tilanus, H
    Welvaart, K
    Sasako, M
    Fleuren, GJ
    Bruijn, JA
    Arends, JW
    Grond, ALN
    vandeStadt, J
    [J]. BRITISH JOURNAL OF SURGERY, 1996, 83 (05) : 672 - 674
  • [5] BENEFIT OF AGGRESSIVE MULTIMODALITY TREATMENT FOR GASTRIC-CANCER
    BRENNAN, MF
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (04) : 286 - 287
  • [6] Lymph-node dissection for gastric cancer
    Brennan, MF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12) : 956 - 958
  • [7] Peritoneal lavage cytology in gastric cancer: An independent predictor of outcome
    Burke, EC
    Karpeh, MS
    Conlon, KC
    Brennan, MF
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (05) : 411 - 415
  • [8] Fujii S, 2002, J EXP CLIN CANC RES, V21, P547
  • [9] Fujimura T, 1998, J SURG ONCOL, V69, P71, DOI 10.1002/(SICI)1096-9098(199810)69:2<71::AID-JSO5>3.0.CO
  • [10] 2-R